Protea Biosciences (PRGB) 0.4500 $PRGB Protea Highlights

Protea Biosciences (PRGB) 0.4500 $PRGB

Protea Highlights New Mass Spec Imaging and Bioanalytical Workflows at ASMS
Marketwired - Mon Jun 01, 7:57AM CDT
Protea Biosciences Group, Inc. (OTCQB: PRGB) ("Protea" announced today that it is presenting a variety of new applications using the Company's proprietary mass spec imaging system and bioanalytical workflows at the 63rd American Society of Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, held in St. Louis, MO. The eight posters to be presented by Protea scientists include the following:

Protea Announces Commercial Release of REDIchip(TM)
Marketwired - Mon Jun 01, 7:57AM CDT
Protea Biosciences Group, Inc. (OTCQB: PRGB) ("Protea" announced today that it is launching a new chip-based technology at the 63rd American Society of Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, held in St. Louis, MO. The nanopost array technology, called REDIchip(TM) (Resonance-Enhanced Desorption Ionization), was invented in the laboratory of Akos Vertes, PhD., Department of Chemistry, The George Washington University, and exclusively licensed to Protea.

Protea Launches New Mass Spec Technology
GlobeNewswire - Mon Jun 01, 7:00AM CDT
Protea Biosciences Group, Inc. (OTCQBRGB) ("Protea" announced today a new, silicon chip technology that enables the rapid identification and quantitation of small molecules in biofluids. The announcement was made at the 63 American Society of Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, held in St. Louis, MO.

Protea Announces Completion of Private Placement
GlobeNewswire - Mon Apr 27, 2:00PM CDT
Protea Biosciences Group, Inc. (OTCQBRGB) ("Protea" announced today that it has closed on total gross proceeds of $7,415,551 million from the private placement offering of preferred stock and 3-year warrants to existing and new accredited investors, which included the conversion of $2,146,977 of existing loans from shareholders. (The preferred stock has subsequently converted into common stock.) The Company will use the proceeds to provide working capital for general corporate purposes, including the ongoing expansion of bioanalytical services and core technology development.

Protea to acquire vivoPharm and intends to develop and market new services for pharmaceutical R&D
M2 - Tue Apr 07, 7:19AM CDT
Molecular information company Protea Biosciences Group (OTCBBRGB) on Tuesday disclosed that it has entered into an agreement to acquire vivoPharm Pty for an undisclosed amount.

Protea Bio buys biopharma services firm
Seeking Alpha - at Seeking Alpha - Tue Apr 07, 7:00AM CDT


Protea Announces Agreement to Acquire vivoPharm
GlobeNewswire - Tue Apr 07, 6:30AM CDT
Protea Biosciences Group, Inc. (OTCQBRGB) ("Protea" announced today that it has entered into an agreement dated as of March 31, 2015 for the purchase of vivoPharm Pty Ltd. ("vivoPharm", a global provider of pharmacology, toxicology and bioanalytical research services, with a portfolio of proprietary oncology models.

IPOs & Transactions Week in Review: February 9 - 13 / plus free S-1 workflow whitepaper
PR Newswire - Mon Feb 16, 11:21AM CST
Vintage, the capital markets, corporate services and institutional & fund services division of PR Newswire, has released its weekly IPO and Transaction summary.
VUZI: 6.32 (+0.06)

Purdue acquires LAESI Technology from Protea for herbicide research applications
M2 - Fri Jan 16, 7:31AM CST
Molecular information company Protea Biosciences Group (OTC BBRGB) disclosed on Thursday the sale of its LAESI DP-1000 Instrument System to Purdue University for an undisclosed amount.

Purdue Acquires Protea's LAESI(R) Technology
GlobeNewswire - Thu Jan 15, 7:59AM CST
Protea Biosciences Group, Inc. (OTCQBRGB) ("Protea" announced today that Purdue University has acquired Protea's LAESI DP-1000 Instrument System for direct molecular analysis. The system will be used in Purdue's College of Agriculture, the Department of Botany and Plant Pathology, for the molecular imaging of herbicide active ingredients and other related compounds to optimize herbicide applications and improve weed management.

Protea Launches New Tissue Analytics Software and Workflow
GlobeNewswire - Mon Jan 12, 10:16AM CST
Protea Biosciences Group, Inc. (OTCQBRGB) ("Protea" announced today that it has developed a new software platform, known as "Histology Guided Mass Spec Imaging (HG-MSI)", that enables pathologists to combine traditional microscopy and histology with high resolution mass spectrometry molecular imaging. The Company made the announcement today while presenting at the Biotech Showcase(TM) 2015 Conference being held in San Francisco, CA along with the J.P. Morgan 33 Annual Healthcare Conference.

Protea Biosciences to Present at Biotech Showcase(TM) 2015
GlobeNewswire - Wed Jan 07, 7:30AM CST
Protea Biosciences Group, Inc. (OTCQBRGB) ("Protea", "the Company" announced today that Stephen Turner, CEO and Chairman, will be presenting at the Biotech Showcase(TM) 2015 Conference being held in San Francisco, CA.

Protea Biosciences to Present at LD Micro Conference
GlobeNewswire - Tue Dec 02, 7:30AM CST
Protea Biosciences Group, Inc. (OTCQBRGB) ("Protea", "the Company" announced today that its CEO and Chairman, Stephen Turner, will present at the 7 annual LD Micro "Main Event" Micro-Cap Growth Conference on Thursday, Dec. 4 at 1:00 p.m. PT. The conference will be held at the Luxe Sunset Bel Air Hotel, in Los Angeles, California.

Protea Biosciences Announces 2014 Third Quarter Financial Results
GlobeNewswire - Tue Nov 18, 8:00AM CST
Protea Biosciences Group, Inc. (OTCQBRGB) ("Protea" or the "Company" announced today that it has reported financial results for its third quarter ended September 30, 2014. Gross revenue in the third quarter of 2014 totaled $517,569, a 190% increase compared to the third quarter of 2013 and the highest revenue for any quarter in the Company's history. Gross revenue for the nine months ended September 30, 2014 totaled $1,332,230, compared to $938,080 for the same period of 2013, representing a 42% increase. The Company's two core lines of business, molecular information services and LAESI instrument platforms, showed greater than 200% increases in gross revenues for the third quarter period over the same period in 2013.

Protea Biosciences Releases Mass Spectrometry Imaging Data for Characterizing 3D Microtissues
GlobeNewswire - Thu Nov 06, 7:43AM CST
Protea Biosciences Group, Inc. (OTCQBRGB) announced today that is has released the presentation titled, "Mass spectrometry imaging for the characterization of 3D microtissues," which was presented by Dr. Erin Seeley of Protea at the InSphero AG user group meeting held in San Francisco, California on October 24, 2014. The presentation can be found through the following link.

Protea Biosciences Group divests LAESI DP-1000 Instrument System to Princeton University
M2 - Thu Oct 16, 5:28AM CDT
Molecular information company Protea Biosciences Group (OTC BBRGB) revealed on Wednesday the sale of its LAESI DP-1000 Instrument System for direct molecular analysis to Princeton University.

Princeton University Acquires Protea's LAESI(R) Technology Platform
GlobeNewswire - Wed Oct 15, 7:30AM CDT
Protea Biosciences Group, Inc. (OTCQBRGB) ("Protea" announced today that Princeton University has purchased Protea's LAESI DP-1000 Instrument System for direct molecular analysis. The system will be used in Princeton's Frick Chemistry Laboratory for the screening of microbial samples to identify new molecular entities that may hold promise as new antimicrobial therapeutics.